These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

405 related articles for article (PubMed ID: 34168432)

  • 21. Peptide-functionalized and high drug loaded novel nanoparticles as dual-targeting drug delivery system for modulated and controlled release of paclitaxel to brain glioma.
    Di Mauro PP; Cascante A; Brugada Vilà P; Gómez-Vallejo V; Llop J; Borrós S
    Int J Pharm; 2018 Dec; 553(1-2):169-185. PubMed ID: 30321641
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Polymer Nanoparticles with 2-HP-β-Cyclodextrin for Enhanced Retention of Uptake into HCE-T Cells.
    Qin Z; Li B; Deng Q; Wen Y; Feng S; Duan C; Zhao B; Li H; Gao Y; Ban J
    Molecules; 2024 Jan; 29(3):. PubMed ID: 38338402
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Brigatinib loaded poly(d,l-lactide-co-glycolide) nanoparticles for improved anti-tumoral activity against non-small cell lung cancer cell lines.
    Ahmed MM; Fatima F; Anwer MK; Aldawsari MF; Bhatia S; Al-Harrasi A
    Drug Dev Ind Pharm; 2021 Jul; 47(7):1112-1120. PubMed ID: 34551665
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Uniform carboxymethyl chitosan-enveloped Pluronic F68/poly(lactic-co-glycolic acid) nano-vehicles for facilitated oral delivery of gefitinib, a poorly soluble antitumor compound.
    Wang J; Wang F; Li X; Zhou Y; Wang H; Zhang Y
    Colloids Surf B Biointerfaces; 2019 May; 177():425-432. PubMed ID: 30798063
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cyclodextrin modified erlotinib loaded PLGA nanoparticles for improved therapeutic efficacy against non-small cell lung cancer.
    Vaidya B; Parvathaneni V; Kulkarni NS; Shukla SK; Damon JK; Sarode A; Kanabar D; Garcia JV; Mitragotri S; Muth A; Gupta V
    Int J Biol Macromol; 2019 Feb; 122():338-347. PubMed ID: 30401652
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics and biodistribution of paclitaxel-loaded microspheres.
    Yan F; Tang S; Fu Q
    Arzneimittelforschung; 2012 Apr; 62(4):176-80. PubMed ID: 22270845
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In-vitro evaluation of paclitaxel-loaded MPEG-PLGA nanoparticles on laryngeal cancer cells.
    Gao C; Pan J; Lu W; Zhang M; Zhou L; Tian J
    Anticancer Drugs; 2009 Oct; 20(9):807-14. PubMed ID: 19696655
    [TBL] [Abstract][Full Text] [Related]  

  • 28. GSH-responsive poly-resveratrol based nanoparticles for effective drug delivery and reversing multidrug resistance.
    Liping Y; Jian H; Zhenchao T; Yan Z; Jing Y; Yangyang Z; Jing G; Liting Q
    Drug Deliv; 2022 Dec; 29(1):229-237. PubMed ID: 35001781
    [TBL] [Abstract][Full Text] [Related]  

  • 29. iRGD Co-Administration with Paclitaxel-Loaded PLGA Nanoparticles Enhance Targeting and Antitumor Effect in Colorectal Cancer Treatment.
    Li L; Yang M; Li R; Hu J; Yu L; Qian X
    Anticancer Agents Med Chem; 2021; 21(7):910-918. PubMed ID: 32698755
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Controlled Release, Intestinal Transport, and Oral Bioavailablity of Paclitaxel Can be Considerably Increased Using Suitably Tailored Pegylated Poly(Anhydride) Nanoparticles.
    Calleja P; Espuelas S; Vauthier C; Ponchel G; Irache JM
    J Pharm Sci; 2015 Sep; 104(9):2877-86. PubMed ID: 25600579
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Integrated multi-omics analysis reveals unique signatures of paclitaxel-loaded poly(lactide-co-glycolide) nanoparticles treatment of head and neck cancer cells.
    Haider M; Jagal J; Bajbouj K; Sharaf BM; Sahnoon L; Okendo J; Semreen MH; Hamda M; Soares NC
    Proteomics; 2023 Aug; 23(16):e2200380. PubMed ID: 37148169
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enhanced intracellular delivery and controlled drug release of magnetic PLGA nanoparticles modified with transferrin.
    Cui YN; Xu QX; Davoodi P; Wang DP; Wang CH
    Acta Pharmacol Sin; 2017 Jun; 38(6):943-953. PubMed ID: 28552909
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro and in vivo investigation on PLA-TPGS nanoparticles for controlled and sustained small molecule chemotherapy.
    Zhang Z; Lee SH; Gan CW; Feng SS
    Pharm Res; 2008 Aug; 25(8):1925-35. PubMed ID: 18509603
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Polydopamine-based surface modification for the development of peritumorally activatable nanoparticles.
    Gullotti E; Park J; Yeo Y
    Pharm Res; 2013 Aug; 30(8):1956-67. PubMed ID: 23609560
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cytotoxicity of paclitaxel incorporated in PLGA nanoparticles on hypoxic human tumor cells.
    Jin C; Bai L; Wu H; Song W; Guo G; Dou K
    Pharm Res; 2009 Jul; 26(7):1776-84. PubMed ID: 19384463
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Spermidine-mediated poly(lactic-
    Tang J; Li J; Li G; Zhang H; Wang L; Li D; Ding J
    Int J Nanomedicine; 2017; 12():6687-6704. PubMed ID: 28932114
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Development of a novel morphological paclitaxel-loaded PLGA microspheres for effective cancer therapy: in vitro and in vivo evaluations.
    Zhang Z; Wang X; Li B; Hou Y; Yang J; Yi L
    Drug Deliv; 2018 Nov; 25(1):166-177. PubMed ID: 29299936
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Co-delivery of cisplatin and paclitaxel by folic acid conjugated amphiphilic PEG-PLGA copolymer nanoparticles for the treatment of non-small lung cancer.
    He Z; Huang J; Xu Y; Zhang X; Teng Y; Huang C; Wu Y; Zhang X; Zhang H; Sun W
    Oncotarget; 2015 Dec; 6(39):42150-68. PubMed ID: 26517524
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hybrid Nanoparticle for Co-delivering Paclitaxel and Dihydroartemisinin to Exhibit Synergic Anticancer Therapeutics.
    Tran BN; Ninh TTK; Do TT; Do PT; Nguyen CN
    Curr Cancer Drug Targets; 2024; 24(12):1250-1261. PubMed ID: 38321897
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Solid lipid nanoparticles of paclitaxel strengthened by hydroxypropyl-β-cyclodextrin as an oral delivery system.
    Baek JS; So JW; Shin SC; Cho CW
    Int J Mol Med; 2012 Oct; 30(4):953-9. PubMed ID: 22859311
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.